Enliven Capital Lease Obligations from 2010 to 2025
| ELVN Stock | 21.07 0.44 2.05% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 89.5 K |
Check Enliven Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enliven Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 100.9 M, Research Development of 84.8 M or Total Operating Expenses of 109.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.59. Enliven financial statements analysis is a perfect complement when working with Enliven Therapeutics Valuation or Volatility modules.
Enliven | Capital Lease Obligations |
Latest Enliven Therapeutics' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Enliven Therapeutics over the last few years. Enliven Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Enliven Therapeutics asset purchases. For example, Enliven Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Enliven Therapeutics control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Enliven Therapeutics' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enliven Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Enliven Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 123,250 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 72.59 | |
| Mean Deviation | 55,906 | |
| Median | 105,000 | |
| Standard Deviation | 89,465 | |
| Sample Variance | 8B | |
| Range | 335K | |
| R-Value | 0.15 | |
| Mean Square Error | 8.4B | |
| R-Squared | 0.02 | |
| Significance | 0.58 | |
| Slope | 2,838 | |
| Total Sum of Squares | 120.1B |
Enliven Capital Lease Obligations History
About Enliven Therapeutics Financial Statements
Enliven Therapeutics investors utilize fundamental indicators, such as Capital Lease Obligations, to predict how Enliven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year |
Check out the analysis of Enliven Therapeutics Correlation against competitors. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.